In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the use of nalmefene in the management of alcohol dependence. Although the drug has been approved for use in the NHS, DTB's editorial highlights limitations of the evidence supporting its use and discusses concerns raised by three groups of researchers. Currently, the NHS in England spends £20,000 per month on the drug in primary care.

Read the full editorial here: http://dtb.bmj.com/content/54/9/97.full.

There’s also a review of the management of hidradenitis suppurativa. Article accessible here: http://dtb.bmj.com/content/54/9/102.full.